DEXCOM (DXCM) Company Report

Dexcom delivered $4.662 billion in full-year 2025 revenue (up 16%, 15% organic) and exited with 3.5 million active customers; Stelo contributed $130 million of revenue.
For 2026, the company guides to $5.16 billion–$5.25 billion in revenue (+11%–13%), with expanded gross margin, 22%–23% operating margin, $1 billion free cash flow, and $1.5 billion adjusted EBITDA.
Recent product highlights include full rollout of the G7 15-day sensor and approval of Smart Basal; the upcoming G8 platform targets a 50% smaller wearable and enhanced accuracy, alongside Stelo app enhancements.
To support growth and new products, Dexcom’s Ireland sensor manufacturing facility is on track to begin production in Q4 2026.

1 day ago

Transcript

Dexcom reports 2025 results and 2026 growth guidance

DXCM

Guidance Update

Product Launch

New Projects/Investments

FY2025 revenue of $4.662 billion, up 16% (15% organic), with 3.5 million active customers (+20% YoY)
2026 guidance: revenue $5.16–5.25 billion (+11–13%), operating margin 22–23%, $1 billion free cash flow, $1.5 billion adjusted EBITDA
Product pipeline: approved Smart Basal, full US launch of G7 15-day sensor, previewed next-gen G8 system, and Ireland manufacturing facility to start production in Q4 2026
Coverage expansion: top three US PBMs now cover CGM for all diabetes patients; targeting new access in Western Europe, Australia, and non-insulin type 2 markets supported by registry and upcoming RCT data

1 day ago

Transcript

Dexcom provides 2026 guidance and growth strategy at JPM Healthcare Conference

DXCM

Guidance Update

Product Launch

Dexcom reported preliminary 2025 revenue of $4.662 billion (organic growth ~15%) and grew its active user base by over 20% to approximately 3.5 million globally.
For fiscal year 2026, Dexcom guided to $5.16–$5.25 billion in revenue (~11–13% growth), non-GAAP gross margin of ~63–64%, and non-GAAP operating margin of ~22–23%.
Key product innovations include the launch of the G7 15 Day CGM, FDA clearance for Dexcom Smart Basal, and expansion of Stelo to ~500,000 users generating ~$130 million in 2025 revenue.
Dexcom is expanding international manufacturing with an Ireland facility on track for Q4 2026 production, and has integrated CGM data into 160+ health systems via Dexcom Direct EHR.

1 day ago

Presentation

Dexcom outlines strategic priorities and 2026 guidance

DXCM

Management Change

Guidance Update

Product Launch

As his first conference as President & CEO, Jake Leach set three strategic priorities: becoming the premier glucose solution for all customers, delivering a best-in-class customer experience, and expanding international market share.
Dexcom reported 2025 revenue of $4.662 billion, up 16% (15% organic), with an active customer base of 3.5 million, excluding Stelo, which generated $130 million in revenue.
For 2026, the company forecasts $5.16–5.25 billion in revenue (11–13% growth), 22–23% operating margin, $1 billion in free cash flow, and $1.5 billion in adjusted EBITDA.
Key product developments include the launch of Smart Basal and the G7 15-day sensor, the upcoming G8 with a 50% smaller wearable and enhanced accuracy, and a new Ireland manufacturing facility slated to begin production in Q4 2026.

1 day ago

Transcript

Dexcom reports preliminary Q4 2025 results and 2026 outlook

DXCM

Earnings

Guidance Update

Dexcom reported Q4 2025 preliminary revenue of $1.260 billion, up 13% year-over-year, with U.S. revenue of $892 million (+11%) and international revenue of $368 million (+18%).
For fiscal 2025, preliminary revenue was $4.662 billion, a 16% increase over 2024, and the company reiterated its non-GAAP gross profit margin guidance of ~61% and non-GAAP operating margin guidance of 20–21%.
2026 outlook includes total revenue of $5.16–$5.25 billion (11–13% growth), non-GAAP gross profit margin of 63–64%, and non-GAAP operating margin of 22–23%.
Audited Q4 and FY2025 results will be released on February 12, 2026, followed by a conference call at 4:30 p.m. ET.

1 day ago

8-K

Dexcom reports preliminary Q4 2025 results and initial 2026 outlook

DXCM

Earnings

Guidance Update

Product Launch

Dexcom reported Q4 2025 revenue of ~$1.260 billion, up 13% year-over-year (U.S.: $892 million, +11%; International: $368 million, +18%).
Fiscal 2025 revenue preliminarily reached $4.662 billion, a 16% increase over 2024, with non-GAAP gross profit margin guidance reiterated at ~61% and operating margin at 20–21%.
For 2026, Dexcom expects revenue of $5.16–5.25 billion (11–13% growth), non-GAAP gross margin of 63–64%, and operating margin of 22–23%.
The company highlighted the initial launch of its G7 15 Day sensor system, supporting continued innovation and market expansion in 2026.

1 day ago

Press Release

Dexcom appoints Jake Leach as CEO

DXCM

CEO Change

Product Launch

New Projects/Investments

Jake Leach began his tenure as President and CEO on Jan. 1, 2026, succeeding Kevin Sayer after guiding Dexcom through over a decade of growth.
He is scheduled to present Dexcom’s 2026 vision at CES 2026 on Jan. 7 and at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 12.
A reimagined Stelo app with AI-enabled insights and macronutrient food logging, plus the pharmacy launch of the G7 15 Day CGM System, will roll out in early 2026.
Dexcom plans continued portfolio investments and has expanded coverage for its glucose biosensing technology to several million additional people globally over the past two years.

6 days ago

Press Release

Dexcom receives FDA clearance for Smart Basal insulin optimizer

DXCM

Product Launch

Dexcom secured FDA clearance for Smart Basal, the first CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes on glargine U-100 therapy.
The system leverages data from the Dexcom G7 15-Day sensor and user-logged insulin doses to provide personalized daily basal dose recommendations, reducing trial-and-error and hypoglycemia fears.
Smart Basal automatically lowers dose suggestions after hypoglycemic events by a provider-defined amount, enhancing safety.
Healthcare providers can prescribe and configure Smart Basal via Dexcom Clarity, with recommendations delivered through the Dexcom G7 app for streamlined patient use.

Nov 19, 2025, 4:24 PM

Morningstar

DexCom shareholders eligible for class action alleging unauthorized device changes

DXCM

Legal Proceedings

Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that the deadline to move for lead plaintiff in the DexCom (NASDAQ: DXCM) securities class action is December 26, 2025; the Class Period runs from July 26, 2024 to September 17, 2025.
The lawsuit alleges DexCom made unauthorized design changes to its G6 and G7 continuous glucose monitoring devices without FDA approval, overstating their reliability and downplaying health risks.
Key events include a March 10, 2025 FDA Warning Letter citing “adulteration” of G6/G7 sensors—stock fell $7.12 to $70.72—and subsequent declines on public disclosures and a September 2025 Hunterbrook report revealing device failures and fatalities.
Investors who acquired DexCom securities during the Class Period should submit their application by the December 26, 2025 deadline to participate in the litigation.

Nov 11, 2025, 2:18 PM

Press Release

Dexcom faces securities class action over G7 accuracy allegations

DXCM

Legal Proceedings

BLB&G filed a securities class action in the U.S. District Court for the S.D.N.Y. against Dexcom and certain executives for alleged violations of federal securities laws.
The suit alleges Dexcom misrepresented the accuracy and reliability of its G7 continuous glucose monitoring device, attributing its success to product quality while concealing defects.
Plaintiffs claim these defects arose from an unapproved sensor coating change in December 2023, which impaired both sensor accuracy and data transmission.
The action, related to Prime v. DexCom, covers investors who acquired Dexcom common stock between January 8, 2024 and September 17, 2025.

Nov 10, 2025, 10:00 PM

Press Release

Earnings Transcripts

Quarterly earnings call transcripts for DEXCOM.

Q3 2025

Oct 30, 2025

→

Q2 2025

Jul 30, 2025

→

Q1 2025

May 1, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Kevin Sayer say about margins?What are DEXCOM's strategic priorities?How is DEXCOM positioned vs competitors?How did DEXCOM do last quarter?

DEXCOM (DXCM)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Kevin Sayer

Jake Leach

Jereme Sylvain

Michael Brown

Sadie Stern

Board Members

Bridgette Heller

Euan Ashley

Kyle Malady

Mark Foletta

Nicholas Augustinos

Renée Galá

Richard Collins

Rimma Driscoll

Steven Altman

Analyst Coverage

Jayson Bedford

Joanne Wuensch

Marie Thibault

Travis Steed

Michael Polark

Shagun Singh Chadha

Danielle Antalffy

Issie Kirby

Joshua Jennings

Steven Lichtman

Anthony Petrone

Bill Plovanic

Brandon Vazquez

Christopher Pasquale

David Roman

Jeffrey Johnson

Larry Biegelsen

Matthew O'Brien

Matthew Taylor

Matt Taylor

Michael Kratky

Richard Newitter

Robbie Marcus

Robert Marcus

William Plovanic

Danielle Antalffy

Jon Block

Matthew Miksic

Matthew O'Brien

Matt Miksic

Mike Kratky

Colin Clark

Kyle Rose

Larry Beagleson

Lawrence Biegelsen

Margaret Kaczor Andrew

Mathew Blackman

Matt O'Brien

Mike Polark

Patrick Wood

Simran

Latest news

Earnings Transcripts

Q3 2025

Q2 2025

Q1 2025

Ask Fintool AI Agent